AcuVid™ Expands Products

In addition to testing of the AcuVid COVID-19 15-Minute Rapid Antigen Saliva Test being conducted in Canada and Brazil, the Company announced entering into an exclusive distribution agreement to white label and distribute their COVID-19 15-minute rapid antibody test, which detects both IgG and IgM antibodies that fight against SARS-CoV-2 (COVID-19). To be branded Therma Bright’s AcuVid™ COVID-19 Rapid Antibody Test, this simple pinprick antibody blood test (i.e.: serology test) uses a small amount of blood and has a 96.6% sensitivity for detecting antibodies of SARS CoV-2 in individuals who currently or have been infected with the virus, as well as those individuals who have received COVID-19 vaccines.

This new white-labeled antibody test has already secured CE approval for 27 European nations, as well as ANVISA regulatory clearance in Brazil. Therma Bright will seek additional regulatory approvals in order to sell this test globally.

Smart-enabled AcuVid™ Antigen Test

On April 28, 2021, Therma Bright announced a memorandum of understanding (MOU) agreement to incorporate a secure tracking technology into its premier AcuVid COVID-19 15-Minute Rapid Antigen Saliva Test. (See Press & Media Section). The smart-enabled antigen test is geared to assist communities in safely and securely return to work and play, while using an embedded and encrypted technology for tracking and reporting Covid-19 test results. The smart solution will not only assist in tracking product for quality assurance, shipping and logistics, but will also be used at point-of-care for reporting test results. The smart-enabled solution also paves the way for Therma Bright to prepare its AcuVID COVID-19 Rapid Antigen Test for at-home testing governmental approval and personal use.

Overall, this smart-enabled AcuVid™ test will track and help individuals manage their results on a real-time basis for the millions of tests the Company plans to deploy around the world. And with this encrypted technology, millions of test results can then be shared safely and securely with government agencies, workplaces, entertainment venues and more.

Rob Fia, CEO of Therma Bright, believe that their premier, smart-enabled AcuVid COVID-19 Rapid Antigen Test will provide a “Brighter Experience” - a complete end-to-end solution that ensures product tracking, quality control and test validation data are all cryptographically captured and secured to protect individual privacy with every test taken.

The opportunity of working with such lead-edge technology will allow Therma Bright to further help in mitigating community spread of the original COVID-19 virus (Wuhan SARS-CoV-2), as well as growing list of variants, including the Brazilian P.1 and P.2 and the UK B.1.1.7 variants. Three variants which the Company has successfully detected in their research with the Federal University of Minas Gerais (UFMG) in Brazil.

All in all, things are looking better and brighter each day with Therma Bright and its ongoing pursuit to bring its innovative COVID19 diagnostic test to the global marketplace.
CEO Update

It’s been an exciting FYQ3, 2021 for Therma Bright. During the quarter the team and our partners have been focused on bringing our premier, smart-enabled AcuVid COVID-19 15-Minute Rapid Antigen Saliva Test to the marketplace, as we deftly maneuver through regulatory issues and secure approvals and certifications.

We kick off the quarter with announcing our approval and preparation for clinical trials, and successfully achieved the results we were seeking with our Brazilian partners at Federal University of Minas Gerais. Furthermore, we have since be able to not only detect the original novel coronavirus (Wuhan SARS-CoV-2 / COVID-19), but also its growing list of variants including the Brazilian P.1 and P.2 and the UK B.1.1.7 variants.

In addition, during the quarter we announced numerous partnerships that are leading to new business development opportunities as well as US federal, state and local policy support. These partnerships have led to discussions on opening global manufacturing and distribution networks, as well as embedding a new smart, encrypted technology on each AcuVid COVID-19 Rapid Antigen Saliva Test for quality control, tracking and reporting. Equally important, we started to secure governmental approvals for AcuVid COVID-19 Rapid Antigen Saliva Test, by securing CE- approval, and a subsequent preliminary order upon demonstrating test results and meeting production capabilities by end of June 2021.

In the coming quarter we look to secure FDA emergency use authorization (EUA) for our smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test first for point-of-care use, and then for at-home use. As we push forward on this, our team and partners are focused on driving new business and sales across EU and the Americas; all with the goal to help mitigate the spread of this horrific virus upon our global citizens.

We’re also excited to begin offering our latest COVID-19 diagnostic test - the AcuVid COVID-19 Rapid Antibody Test. Our new white-label test solution offers a 15-minute rapid COVID-19 antibody test to detect IgG and IgM antibodies that help our bodies fight against SARS-CoV-2. With a small amount of blood, this simple pinprick antibody blood test (i.e.: serology test) offers a 96.6% sensitivity for detecting antibodies of SARS CoV-2 in individuals who are or have been infected by the virus or who have also received the COVID-19 vaccines.

It’s going to be an exciting quarter, and we look forward to keeping you posted on our progress.

Cheers,
Rob

Investor Relations

During FYQ3, 2021, Therma Bright saw some new highs in its share price, reaching $0.54 CAD on March 30 and April 5, 2021 respectively, and saw a low of $0.275 CAD on March 3, 2021, as references in the chart for the quarter - February 1 - April 30, 2021. The closed Q2, 2021 on January 29, 2021 at $0.52 CAD, and close April 30, 2021 at $0.44 CAD, as noted in red on the chart below.

All in all, Rob Fia, CEO of Therma Bright believes it was a good quarter for investors who witnessed a great deal of movement and advancement in bringing the Company’s premier, smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test to the marketplace with CE approval, and efforts to secure FDA emergency use authorization and Health Canada approvals respectively. In addition the addition of key strategics partners with Ridge Global, McWilliams Collective, Afero.io and Federal University of Minas Gerais.

And for Q4? It has started out pretty great! After all, the Company kicked it off with white-label exclusive distribution partnership with its AcuVid™ COVID-19 Rapid Antibody Test, a serological/blood test that will be needed in the months ahead to determine your antibody levels to fight off this nasty novel coronavirus (SARS CoV-2).
AcuVid™ Production Ramp-up
By Ian Levine

Manufacturing plans are moving forward at an accelerated pace. Therma Bright has secured four (4) manufacturing partners across four (4) countries, in order to properly service the global demand and marketplace, while supporting our customers around the world. The Company continues its efforts to put manufacturing relationships into place, which will allow an increase in production capacity to quickly meet sales growth, as well as maintain an agile and low-cost production cost platform.

Therma Bright will continue to integrate its manufacturing and production efforts to meet future needs of and help those markets with critical testing needs for our AcuVid COVID-19 diagnostic tests. Additional updates on manufacturing and production will come during FYQ4, 2021 in press announcements, and in our next Q4/FY2021 Newsletter, expected out in August 2021.

Press & Media Coverage

April 30, 2021: Top 5 Stories of the Week: Therma Bright (TSXV:THRM), ScreenPro (CSE:SCRN), PyroGenesis (TSX:PYR), Naturally Splendid (TSXV:NSP) and Fortuna Silver (TSX:FVI). The Market Herald - Sponsored. Reporter: Jocelyn Aspa (jocelyn.aspa@themarketherald.ca)

April 28, 2021: Therma Bright (TSXV:THRM) partners with Afero to enhance AcuVid(TM) COVID-19 Rapid Antigen Saliva Test. The Market Herald - Health Care, Market News. Reporter: John Ballem (john.ballem@themarketherald.ca)

April 22, 2021: Therma Bright's AcuVid COVID-19 test detects the Brazilian P.1 and P.2 and the UK B.1.1.7 variants. The Market Herald - Health Care, Market News. Reporter: John Ballem (john.ballem@themarketherald.ca)

April 19, 2021: Therma Bright (TSXV:THRM) announces EU-CE approval for AcuVid COVID-19 rapid antigen saliva test and secures conditional sale of 100,000 CE-only AcuVid test kits. The Market Herald - Health Care, Market News. Reporter: John Ballem (john.ballem@themarketherald.ca)


February 26, 2021: Therma Bright (TSXV:THRM) enters into clinical trial agreement for its AcuVid COVID-19 rapid antigen test. The Market Herald - Health Care, Market News. Reporter: John Ballem (john.ballem@themarketherald.ca)